The DIA Europe Conference will take place in Basel, Switzerland from March 18-20, 2025, and we are excited to be a part of it!
Visit us at Booth #F5 and meet our experts to learn how to keep up with the evolving regulatory landscape, manage drug safety commitments, and design risk minimization strategies for your medicinal products and medical devices.
- Dr Purav Thakkar, Vice-President, Pharmacovigilance Operations
- Dr Frank Laschewski, European Qualified Person for Pharmacovigilance
- Dr Kanwalpreet Kaur, UK-QPPV & Head of Strategic Development Group
About DIA Europe
DIA Europe 2025 is one of the largest global conferences which provides an opportunity to connect with key leaders from the healthcare and pharma sectors. DIA Europe 2025 hosts a variety of sessions from across the drug development lifecycle. It discusses the challenges and innovations from the pharmaceutical arena to keep you updated with the latest developments.
Spotlight Event:
Dr Purav Thakkar will be speaking on the topic of “Benefits of Early Risk Profiling for CAR T-Cell Therapies” in the session of Innovation in Pharmacovigilance CAR-T, Gene Therapies and New Modalities on Mar 19, 2025, 3:00 – 4:30 pm CET.
Key Learning Objectives:
Discover how early risk profiling of a CAR T-cell therapies can:
- Help in designing comprehensive Risk Management strategies
- Implement early Risk minimization measures
- Guide the developers on the pre-clinical and clinical data required for Marketing Authorization
- Accelerate approval timelines
- Enhance product quality and in turn Improve patient safety
Presentation Overview:
Join Dr Thakkar as he provides insights into the objectives and methodology of early risk profiling of CAR T-cell therapy and implementation of early risk management strategies. While these therapies have shown remarkable effectiveness in treating lymphomas and advanced leukemias, their widespread adoption faces several challenges compared to conventional treatments due some common risk associated with these therapies. And risk factors for these risks are multifactorial. Early identification of Risk – Risk factors relationship will enable the developers to implement adequate and timely risk minimization measures.
Key Topics Covered:
- Common Risks associated with CAR-T cell therapies.
- Objectives and Benefits of Early Risk profiling of a CAR-T cell therapies in early developmental stage.
- Analysis of Risk – risk factor relationships e.g. Vector-based, disease-related, patient-based risk factors etc
- Approaches to risk management
Why Attend?
This presentation offers valuable insights for:
- Pharmaceutical industry professionals focused on advanced therapies
- Regulatory affairs specialists
- Pharmacovigilance professionals
- Clinical research organizations
- Healthcare professionals involved in cancer treatment
